As a successor to the 2019 Voluntary Scheme for Branded Medicines Access and Pricing is being negotiated, Leela Barham asks where rebates should go in future - that is, if rebates remain at
Moderna’s first attempt to expand its commercial activities beyond COVID-19 vaccines, its respiratory syncytial virus (RSV) shot, has suffered a delay in the US.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.
